The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

The European Commission has launched a pilot program to simplify the approval process for certain clinical studies conducted ...

US pharma major Bristol Myers Squibb has announced that the Phase II TRANSCEND FL trial evaluating Breyanzi (lisocabtagene ...

French drugmaker Ipsen today released final results from the Phase III CheckMate -9ER trial of Cabometyx (cabozantinib) in ...

Q32 Bio (Nasdaq: QTTB) has announced a corporate restructuring, shifting its focus entirely to the development of its lead ...

Reacting to press reports, Germany’s Merck KGaA has confirmed it is in advanced discussions with SpringWorks Therapeutics with the aim of acquiring the US biotechnology company.

On Sunday night, one of the USA’s largest compounders, Hims & Hers, ran a multi-million dollar Super Bowl advert about its ...

Boehringer Ingelheim today revealed that the FIBRONEER-ILD trial of nerandomilast met its primary endpoint, which was the ...

Eli Lilly has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to ...

New Jersey, USA-based clinical-stage biotech Imunon has appointed Dr Douglas Faller as chief medical officer, effective 18, ...

The Indian subsidiary of French pharma major Sanofi has received marketing authorization for Rezurock (belumosudil tablets) in India.

In a statement on Friday, the USA’s National Institutes of Health (NIH) said it would cut grants for "indirect costs" related ...